title: Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports.
authors.affiliation: Institute of Hematology and Medical Oncology L. e A. Seràgnoli, University of Bologna, Bologna, Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Broccoli
authors.forename: Enrico
authors.initials: E
authors.lastname: Derenzini
authors.forename: Cinzia
authors.initials: C
authors.lastname: Pellegrini
authors.forename: Riccardo
authors.initials: R
authors.lastname: Narducci
authors.forename: Giulia
authors.initials: G
authors.lastname: Stefani
authors.forename: Beatrice
authors.initials: B
authors.lastname: Casadei
authors.forename: Lisa
authors.initials: L
authors.lastname: Argnani
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Zinzani
mesh_terms: D000368:Aged; D000079963:Brentuximab Vedotin; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects / Q000627:therapeutic use*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D016410:Lymphoma, T-Cell, Cutaneous / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D012008:Recurrence
chemical_list: D018796:Immunoconjugates; D000079963:Brentuximab Vedotin
keywords: Anaplastic large cell lymphoma; Anaplastic lymphoma kinase negative; Brentuximab vedotin; Cutaneous T-cell lymphoma; Immunotherapy